Full Press Release Details
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3.
IMMP
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Key Takeaway: Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Price reaction · baseline $2.1 (2023-06-16 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)